Citation Impact
Citing Papers
Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix
2000 Standout
OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
2012 Standout
Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2
2003 StandoutScience
Laparoscopy Compared With Laparotomy for Comprehensive Surgical Staging of Uterine Cancer: Gynecologic Oncology Group Study LAP2
2009 Standout
Effect of BRCA1/2 Mutations on Long-Term Survival of Patients With Invasive Ovarian Cancer: The National Israeli Study of Ovarian Cancer
2007
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Mutational landscape and significance across 12 major cancer types
2013 StandoutNature
Mismatch Repair-dependent Iterative Excision at Irreparable O6-Methylguanine Lesions in Human Nuclear Extracts
2006 StandoutNobel
Multidrug resistance in cancer: role of ATP–dependent transporters
2002 Standout
Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence
2007 Standout
Methylation and silencing of the retinoic acid receptor-β2 gene in cervical cancer
2002
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer
1999 Standout
BRCA1 and BRCA2: 1994 and beyond
2004
TGF-β and cancer
1999
Inflammation and cancer
2002 StandoutNature
Cisplatin, Radiation, and Adjuvant Hysterectomy Compared with Radiation and Adjuvant Hysterectomy for Bulky Stage IB Cervical Carcinoma
1999 Standout
Prevalence and Penetrance of Germline BRCA1 and BRCA2 Mutations in a Population Series of 649 Women with Ovarian Cancer
2001
Role of Transforming Growth Factor β in Human Disease
2000 Standout
Role of cytoreduction in stage III and IV uterine papillary serous carcinoma
2007
mRNA-based therapeutics — developing a new class of drugs
2014 StandoutNobel
PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions
2016
Ovarian cancer
2014 Standout
Management of occlusion and thrombosis associated with long-term indwelling central venous catheters
2009
TGF-β signaling in tumor suppression and cancer progression
2001 Standout
Principles of nanoparticle design for overcoming biological barriers to drug delivery
2015 Standout
Pelvic Radiation with Concurrent Chemotherapy Compared with Pelvic and Para-Aortic Radiation for High-Risk Cervical Cancer
1999 Standout
The emerging role of lncRNAs in cancer
2015 Standout
Significance of “Normal” Endometrial Cells in Cervical Cytology from Asymptomatic Postmenopausal Women Receiving Hormone Replacement Therapy
2001
Programmable RNA Tracking in Live Cells with CRISPR/Cas9
2016 StandoutNobel
Engineering of an enantioselective tyrosine aminomutase by mutation of a single active site residue in phenylalanine aminomutase
2010 StandoutNobel
Identification and Characterization of the Binding Sites of P-Glycoprotein for Multidrug Resistance-Related Drugs and Modulators
2004
The 2001 Bethesda System<SUBTITLE>Terminology for Reporting Results of Cervical Cytology</SUBTITLE>
2002 Standout
Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations
2007
Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck
2004 Standout
Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes.
1997
Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study
2000
Current Management Strategies for Ovarian Cancer
2007
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
2010 Standout
Putting tumours in context
2001 Standout
Ectopic Expression of Nonliganded Retinoic Acid Receptor β Abrogates AP-1 Activity by Selective Degradation of c-Jun in Cervical Carcinoma Cells
2004 StandoutNobel
Antithrombotic Therapy for VTE Disease
2012 Standout
Targeting multidrug resistance in cancer
2006 Standout
Prevalence of the I1307K APC gene variant in Israeli Jews of differing ethnic origin and risk for colorectal cancer
1999
Allelic imbalance regions on chromosomes 8p, 17p and 19p related to metastasis of hepatocellular carcinoma: comparison between matched primary and metastatic lesions in 22 patients by genome-wide microsatellite analysis
2003
The DNA Damage Response: Making It Safe to Play with Knives
2010 Standout
Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results
2011 Standout
Intraepithelial Carcinoma of the Fimbria and Pelvic Serous Carcinoma: Evidence for a Causal Relationship
2007
Modifiers of risk of hereditary breast and ovarian cancer
2002
Systemic sclerosis: a prototypic multisystem fibrotic disorder
2007 Standout
Hereditary Colorectal Cancer
2003 Standout
Chemokines in cancer
2002
Mechanism‐Inspired Engineering of Phenylalanine Aminomutase for Enhanced β‐Regioselective Asymmetric Amination of Cinnamates
2011 StandoutNobel
Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer.
1997
Neuroblastoma
2007 Standout
Microtubules as a target for anticancer drugs
2004 Standout
Overall survival after pelvic exenteration for gynecologic malignancy
2014
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
2012 Standout
Hepatocellular carcinoma pathogenesis: from genes to environment
2006 Standout
TGFβ Signaling in Growth Control, Cancer, and Heritable Disorders
2000 Standout
Extended Field Radiation and Cisplatin for Stage IIB and IIIB Cervical Carcinoma
1997
Surgical results of pelvic exenteration in the treatment of gynecologic cancer
2014
Association Between <emph type="ital">BRCA1</emph> and <emph type="ital">BRCA2</emph> Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer
2012
Inherited Colorectal Polyposis and Cancer Risk of the APC I1307K Polymorphism
1999
Cervical cancer
2019 Standout
Using sulfuramidimidoyl fluorides that undergo sulfur(vi) fluoride exchange for inverse drug discovery
2020 StandoutNobel
Development of Multidrug-Resistance Convertors: Sense or Nonsense?
2000
Population BRCA1 and BRCA2 Mutation Frequencies and Cancer Penetrances: A Kin–Cohort Study in Ontario, Canada
2006
Purification, cloning, and functional expression of phenylalanine aminomutase: The first committed step in Taxol side-chain biosynthesis
2005
Design of multifunctional non-viral gene vectors to overcome physiological barriers: Dilemmas and strategies
2011
Cancer of the Ovary
2004 Standout
Phase II Trial of Thalidomide for Therapy of Radioiodine-Unresponsive and Rapidly Progressive Thyroid Carcinomas
2007
Phase I Study of Infusional Paclitaxel in Combination With the P-Glycoprotein Antagonist PSC 833
2001
Tumour stem cells and drug resistance
2005 Standout
5-Bromo-2-iodopyrimidine: a novel, useful intermediate in selective palladium-catalysed cross-coupling reactions for efficient convergent syntheses
1996
Preparation and Characterization of Liposome-Encapsulated Plasmid DNA for Gene Delivery
2013
RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform
2010
The Three Es of Cancer Immunoediting
2004 Standout
Current Management Strategies for Ovarian Cancer
2007
Wnt signaling and cancer
2000 Standout
Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin.
1999
Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
2002
Preventing Future Cancers by Testing Women With Ovarian Cancer forBRCAMutations
2009
Breast Cancer Risk Following Bilateral Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: An International Case-Control Study
2005 Standout
Screening for Founder Mutations in BRCA1 and BRCA2 in Unselected Jewish Women
2009
Staging classification for cancer of the ovary, fallopian tube, and peritoneum
2013
Structural Investigations into the Stereochemistry and Activity of a Phenylalanine-2,3-aminomutase from Taxus chinensis
2014 StandoutNobel
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
2006 Standout
Genetic susceptibility to non-polyposis colorectal cancer
1999
Aryl−Aryl Bond Formation One Century after the Discovery of the Ullmann Reaction
2002 Standout
The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel.
2000
Specific Recruitment of Antigen-presenting Cells by Chemerin, a Novel Processed Ligand from Human Inflammatory Fluids
2003 Standout
Works of Abbie L. Fields being referenced
Mature Results of a Phase II Trial of Concomitant Cisplatin/Pelvic Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Cervix
1996
Expression of retinoic acid receptor-beta 2 mRNA in normal cervical epithelium and cervical squamous cell carcinoma
1997
BRCA1 and BRCA2 Mutation Analysis of 208 Ashkenazi Jewish Women with Ovarian Cancer
2000
Current Therapies in Ovarian Cancer
2003
Total pelvic exenteration: The Albert Einstein College of Medicine/Montefiore Medical Center Experience (1987 to 2003)
2006
Promising new therapies in the treatment of advanced ovarian cancer
1995
All-trans retinoic acid and interferon-?-2a in patients with metastatic or recurrent carcinoma of the uterine cervix
1997
Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma
2003
Continuous Low-Dose Combined Hormone Replacement Therapy and the Risk of Endometrial Cancer
1997
Upstaging pathologic stage I ovarian carcinoma based on dense adhesions is not warranted: A clinicopathologic study of 84 patients originally classified as FIGO stage II
2010
Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: A brief communication from the New York Phase II consortium
2005
Pattern of Lymph Node Metastases in Clinically Unilateral Stage I Invasive Epithelial Ovarian Carcinomas
2001
How Often Should a Port-A-Cath be Flushed?
2005
A phase I safety and dose escalation trial of docetaxel combined with GEM®231, a second generation antisense oligonucleotide targeting protein kinase A R1α in patients with advanced solid cancers
2005
Allelotype of Papillary Serous Peritoneal Carcinomas
2001
Analysis of MDR1 expression in normal and malignant endometrium by reverse transcription-polymerase chain reaction and immunohistochemistry.
1996
No association of the I1307K APC allele with ovarian cancer risk in Ashkenazi Jews.
1998
Altered expression of transforming growth factor-β1 in cervical neoplasia as an early biomarker in carcinogenesis of the uterine cervix
1996
Altered expression of transforming growth factor-beta 1 in cervical neoplasia as an early biomarker in carcinogenesis of the uterine cervix.
1996
Induction of transforming growth factor beta-1 in cervical intraepithelial neoplasia in vivo after treatment with beta-carotene.
1997
PSC833: initial clinical results in refractory ovarian cancer patients.
1998